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Several hypotheses have been proposed to explain how antiangiogenic drugs enhance the treatment efficacy
of cytotoxic chemotherapy, including impairing the ability of chemotherapy-responsive tumors to regrow af-
ter therapy. With respect to the latter, we show that certain chemotherapy drugs, e.g., paclitaxel, can rapidly
induce proangiogenic bonemarrow-derived circulating endothelial progenitor (CEP)mobilization and subse-
quent tumor homing, whereas others, e.g., gemcitabine, do not. Acute CEP mobilization was mediated, at
least in part, by systemic induction of SDF-1a and could be prevented by various procedures such as treat-
ment with anti-VEGFR2 blocking antibodies or paclitaxel treatment in CEP-deficient Idmutant mice, both of
which resulted in enhanced antitumor effects mediated by paclitaxel, but not by gemcitabine.INTRODUCTION
A number of phase III clinical trials involving bevacizumab, the
humanized antibody against VEGF, in combination with chemo-
therapy administered at the maximum tolerated dose (MTD)
have shown median overall survival (OS) or progression-free sur-
vival (PFS) benefits in metastatic breast, colorectal, and non-small
cell lung cancers (Hurwitz et al., 2004; Sandler et al., 2006; Miller
et al., 2007). These trials include the use of 5-fluorouracil (5-FU)
and irinotecan in first-line colorectal cancer (Hurwitz et al., 2004),Cpaclitaxel in first-line metastatic breast cancer (Miller et al., 2007),
and paclitaxel plus carboplatin in the first-line treatment of non-
small cell lung cancer (Sandler et al., 2006). Despite these suc-
cesses, some other phase III trials utilizing bevacizumab coadmi-
nistered with conventional chemotherapy have failed to show OS
or PFS benefits, e.g., when administered with gemcitabine for the
treatment of pancreatic cancer (Burris and Rocha-Lima, 2008).
Factors such as type of tumor, stage, prior treatment, bevacizu-
mab drug dose, pharmacogenomic status, or the nature of the
chemotherapy drug combined with bevacizumab could all beSIGNIFICANCE
Chemotherapy remains the most commonly employed form of systemic cancer treatment. Although partial or complete
shrinkage of tumormass is frequently induced in chemotherapy-responsive tumors, the survival benefits of such responses
can be compromised by rapid regrowth of the drug-treated tumors. Our results illustrate how rapidly activated systemic
host processes involving induction of certain cytokines and mobilization of circulating endothelial progenitors (CEPs)
from the bone marrow can contribute to recovery of drug-treated tumors and, moreover, how this can be blunted by
combination treatment with a VEGF pathway-targeted antiangiogenic drug. The results also implicate the CXCR4/SDF-1a
pathway in therapy-induced CEP responses mediated by certain chemotherapy drugs, and hence as a potential target for
improving their antitumor effectiveness.ancer Cell 14, 263–273, September 9, 2008 ª2008 Elsevier Inc. 263
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benefit is attained. This serves to emphasize how little is known
about the mechanism (or mechanisms) of action of bevacizumab,
and possibly other antiangiogenic agents, especially when
coadministered with chemotherapy.
Several hypotheses to explain how antiangiogenic drugs act
as chemosensitizing agents have been proposed. One of
them, the vessel normalization hypothesis, is based on the
observation that enhanced tumor vessel leakiness produces el-
evated interstitial fluid pressures in tumors, which can impede
the delivery and diffusion of certain anticancer drugs. In addition,
abnormal tumor vasculature is associated with reduced blood
flow and perfusion, another function impeding chemotherapy
delivery, and also causing tumor hypoxia, which can cause resis-
tance to chemotherapy and radiation. Treatment with certain
antiangiogenic drugs can transiently reverse these abnormalities
and enhance chemotherapy (or radiation therapy), provided that
it is administered during the ‘‘normalization window’’ (Jain, 2005;
Winkler et al., 2004). An alternative or additional mechanism is
related to the property of rapid tumor cell repopulation that can
take place between successive MTD chemotherapy treatments.
Addition of an antiangiogenic drug treatment during the chemo-
therapy drug-free break period should slow down tumor re-
growth and thus increase the degree and durability of the tumor
response (Kerbel, 2006; Hudis, 2005). A third hypothesis, which
essentially provides a mechanistic explanation for the second
hypothesis, is based on our prior preclinical observations re-
garding the induction of circulating endothelial progenitor
(CEP) mobilization after treatment with a cytotoxic agent. We
have demonstrated that lymphoma-bearing NOD/SCID mice
treated with intensive 6 day cycles of MTD cyclophosphamide,
separated by 2 week breaks, exhibit substantial increases in vi-
ability and mobilization of CEPs posttreatment after showing an
initial decline during the cycles of therapy, a phenomenon that
in some respect mimics the rebound of neutrophil counts after
treatment with myeloablative chemotherapy (Bertolini et al.,
2003). We suggested that such a mobilization effect in CEP
levels may contribute to and facilitate tumor cell repopulation
during the subsequent drug-free break that is necessary to allow
recovery from the toxic side effects of such therapy (Bertolini
et al., 2003). This could occur by intrinsically promoting tumor
vasculogenesis/angiogenesis but also by suppressing the ability
of chemotherapy to cause a local antiangiogenic effect in tumors
by targeting the endothelial cells of the growing angiogenic neo-
vasculature (Kerbel, 2006; Browder et al., 2000).
Chemotherapy-induced CEP mobilization—i.e., increases in
CEP levels observed at the end of the first and second cycles
of chemotherapy treatment—is observed in patients treated
with anthracycline- and/or taxane-based neoadjuvant chemo-
therapy (Furstenberger et al., 2006). Furthermore, a surprisingly
robust elevation in CEP levels has also been observed within
hours of treatment with microtubule-inhibiting cytotoxic-like vas-
cular disrupting agents (VDAs) in mice (Shaked et al., 2006). We
also found that CEPs and perhaps other bone marrow (proangio-
genic) cells mobilized by VDA treatment home to and colonize
the remaining viable tumor rim commonly observed after treat-
ment with a VDA. When an antiangiogenic drug, i.e., DC101,
a VEGFR2 blocking antibody, was administered 24 hr prior to
the VDA, the VDA-induced CEP surge was largely blocked and264 Cancer Cell 14, 263–273, September 9, 2008 ª2008 Elsevier Inthe residual viable tumor rim was significantly suppressed, which
was followed by increased antitumor efficacy (Shaked et al.,
2006). In addition, preliminary evidence for the induction of
CEPs after VDA treatment has been reported recently in phase
I clinical trials using the VDAs ZD6126 or AVE8062 (Beerepoot
et al., 2006; Farace et al., 2007) and CA4P (P. Nathan, personal
communication). Overall, these findings suggest that CEPs can
contribute to some and perhaps even much of the rapid regrowth
of tumors after treatment with a VDA.
VDAs have a unique mechanism of action as a result of target-
ing the abnormal vasculature of tumors, causing massive tumor
hypoxia and inducing tumoral necrosis. Such effects could help
trigger the acute CEP mobilization and tumor-homing response.
We therefore decided to analyze the impact of conventional che-
motherapy drugs, which lack such acute and potent vascular
disruptive effects, to determine whether such drugs—still the
mainstay of systemic therapy for metastatic disease—neverthe-
less have similar inductive effects on CEP mobilization and tumor
homing, hence assisting the ability of tumors to recover from
exposure to such agents. We also decided to assess whether
different chemotherapeutic drugs have variable abilities to in-
duce CEP mobilization and whether targeted antiangiogenic
drugs or other agents can block chemotherapy-induced CEP
responses and hence amplify their effectiveness.
RESULTS
Acute Induction in CEP Levels in Peripheral Blood
of Mice Treated with Chemotherapy Drugs
Administered near or at the MTD
To study the impact of chemotherapy on tumor growth and an-
giogenesis mediated by bone marrow-derived CEPs, we asked,
similar to our previous observation with VDAs, whether chemo-
therapy administered at the MTD can induce a rapid induction
in levels of viable CEPs. To this end, non-tumor-bearing BALB/c
mice were treated with a number of different chemotherapy
drugs administered near or at the MTD (in doses indicated in
Table S1 available online), and blood was drawn from the
retro-orbital sinus 4 and 24 hr later. CEP levels were evaluated
using flow cytometry as described previously (Shaked et al.,
2005a; Bertolini et al., 2003). The results in Figure 1 show that
only certain drugs, most notably paclitaxel, 5-FU, and docetaxel,
were found to cause acute elevations in viable CEP levels within
24 hr of a single bolus injection, whereas others failed to do so,
e.g., gemcitabine, cisplatinum, and doxorubicin.
Administration of Antiangiogenic Drug prior
to Chemotherapy-Induced CEP Spike Blocks Rapid
Elevation in CEP Levels
For subsequent studies, we focused on experiments using two
distinct chemotherapy drugs given at MTD, i.e., 50 mg/kg pacli-
taxel, which induced rapid and marked elevations in CEP levels
when administered to C57BL/6 mice, and 500 mg/kg gemcita-
bine, which did not. We first monitored levels of CEPs for up to
96 hr after chemotherapy drug injection in order to rule out de-
layed alterations in CEP levels. To do this, non-tumor-bearing
C57BL/6 mice were treated with either paclitaxel or gemcitabine
at the indicated MTD. Blood was drawn by retro-orbital sinus at
several time points and processed for evaluation of viablec.
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the paclitaxel group increased rapidly within 24 hr and subse-
quently returned to baseline levels by 48 hr. In contrast, levels of
CEPs in the gemcitabine-treated group were maintained at base-
line levels for the first 96 hr. Representative flow cytometry plots
4 hr after treatment are presented in Figure S1A. Next we asked
whether, similar to VDAs, the administration of DC101, an antian-
giogenic anti-mouse VEGFR2 monoclonal antibody (Prewett
et al., 1999), 24 hr prior to chemotherapy could block the rapid
induction in CEP levels. The results in Figure 2B show that when
DC101 was injected 24 hr before chemotherapy, this resulted in
a diminished CEP spike in the paclitaxel-treated mice. No signif-
icant differences in CEP levels were observed in mice treated
with the combination of DC101 and gemcitabine. Similar results
were obtained when G6-31, a monoclonal neutralizing antibody
against both mouse and human VEGF (Liang et al., 2006), was
used in combination with paclitaxel or gemcitabine (Figure S1B).
Rapid Elevation in CEPs after Chemotherapy Treatment
Results in Bone Marrow-Derived Cell Colonization
of Treated Tumors
A growing body of evidence suggests that a number of different
bone marrow-derived cell types promote tumor angiogenesis
and growth by various mechanisms. For example, hemangio-
cytes or recruited bone marrow circulating cells (RBCCs) and
Tie2-expressing monocytes (TEMs) have recently been shown
to reside at perivascular sites and hence promote angiogenesis
in a paracrine manner (Jin et al., 2006; De Palma et al., 2005; Gru-
newald et al., 2006; Udagawa et al., 2006; Kerbel, 2008). In order
to track bone marrow cell homing and retention in treated tu-
mors, experiments were undertaken using GFP+ bone marrow
cells obtained from C57BL/UBI/GFP mice, which were trans-
planted into lethally irradiated C57BL/6 mice (Shaked et al.,
2006). Four weeks later, mice were used as recipients for an
injection of Lewis lung carcinoma (LLC) cells. When tumors
Figure 1. Levels of Viable Circulating Endothelial Progenitors in
Non-Tumor-Bearing BALB/c Mice Treated with a Variety of Chemo-
therapy Drugs near or at the Maximum Tolerated Dose
Eight- to twelve-week-old BALB/c mice (n = 4 or 5 mice per group) were
treated with 30 mg/kg paclitaxel (PTX), 40 mg/kg docetaxel (DOC), 120 mg/kg
gemcitabine (GEM), 11 mg/kg vinblastine (VBL), 100 mg/kg 5-fluorouracil
(5-FU), 250 mg/kg cyclophosphamide (CPA), 6 mg/kg cisplatinum (CDDP),
12 mg/kg doxorubicin (DOX), or 100 mg/kg irinotecan (CPT-11) as indicated
in Table S1. Four and twenty-four hours later, mice were bled via retro-orbital
sinus for evaluation of viable circulating endothelial progenitors (CEPs) by
four-color flow cytometry. Data are expressed as mean ± SD. 0.05 > *p >
0.01; **p% 0.01.Creached 500 mm3, treatment with either bolus-injected MTD
paclitaxel or MTD gemcitabine was initiated. Three days later,
tumors were removed for evaluation of GFP+ bone marrow cell
colonization and incorporation into the tumor vasculature using
both confocal microscopy and flow cytometry techniques, as
described in Experimental Procedures. We detected numerous
bone marrow-derived GFP+ cells in tumors that had been treated
with paclitaxel, in clear contrast to gemcitabine-treated or un-
treated control tumors. When DC101 was administered 24 hr
prior to chemotherapy, a substantial reduction in the number
of GFP+ bone marrow cells was observed in paclitaxel-treated
and untreated tumors. No differences in GFP+ cell numbers
were observed in gemcitabine-treated tumors (Figure 3A;
Figure S2A). Of note, the antiangiogenic effect of DC101 on local
angiogenesis was insignificant within the first 3 days, as demon-
strated previously (Franco et al., 2006).
Next, to further characterize some of the bone marrow cell
types colonizing the tumors, tumors from all groups (n = 5 per
group) were prepared as single-cell suspensions and sub-
sequently stained for evaluation of bone marrow-derived endo-
thelial cells, TEMs, and hemangiocytes using flow cytometry as
described in Experimental Procedures. The results in Figure 3B
Figure 2. Evaluation of CEPs in Mice Treated with Either Paclitaxel
or Gemcitabine in Combination with DC101
(A) Eight- to ten-week-old non-tumor-bearing C57BL/6 mice (n = 4 mice per
group) were treated with 50 mg/kg paclitaxel (PTX) or 500 mg/kg gemcitabine
(GEM). Blood was drawn from the retro-orbital sinus at time points indicated in
the figure and processed for evaluation of viable CEPs using flow cytometry.
(B) In a separate experiment, mice were treated with paclitaxel or gemcitabine
as described in (A), with or without DC101 administered 24 hr prior to chemo-
therapy treatment. Blood was drawn via retro-orbital sinus and processed for
evaluation of viable CEPs using flow cytometry. 0.05 > *p > 0.01; **p% 0.01.
Data are expressed as mean ± SD.ancer Cell 14, 263–273, September 9, 2008 ª2008 Elsevier Inc. 265
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cells as well as increases in hemangiocytes and TEMs (although
the latter two did not reach significance) in the paclitaxel-treated
group. Administration of DC101 prior to chemotherapy treatment
inhibited bone marrow cell colonization of tumors. Overall, these
results suggest that paclitaxel treatment induces bone marrow-
derived cell mobilization and colonization of tumors and hence
may promote tumor cell repopulation and angiogenesis by
various mechanisms.
Enhanced Antitumor and Antiangiogenic Activities
in Mice Treated with Paclitaxel plus DC101
To further characterize the antitumor and antiangiogenic effects
of the combination of paclitaxel plus DC101 in comparison to
Figure 3. Homing and Colonization of GFP+ Bone Marrow Cells
in LLC Tumors after Treatment with Paclitaxel or Gemcitabine
in Combination with DC101
C57BL/6 mice (n = 5 mice per group) lethally irradiated and subsequently
transplanted with 107 GFP+ bone marrow cells obtained from UBI/GFP/
C57BL/6 mice were used as recipients for a subcutaneous injection of Lewis
lung carcinoma (LLC) cells, which were allowed to grow until they reached
500 mm3, at which point treatment with paclitaxel (PTX) or gemcitabine
(GEM) with or without upfront treatment with DC101 was initiated.
(A) Three days later, tumors were removed and sections were prepared for as-
sessment of GFP+ cell colonization of tumors (green), CD31 staining as an en-
dothelial cell (blood vessel) marker (red), and colocalization of CD31 and GFP+
cells in the paclitaxel-treated group (blue arrows). Left scale bar = 20 mm; right
scale bar = 50 mm.
(B) The numbers of bone marrow-derived GFP+ endothelial cells (BM EC), he-
mangiocytes (HEMANGIO), and Tie2-expressing monocytes (TEM) colonizing
tumorswereevaluatedbyflow cytometryusingsingle-cell suspensions prepared
from the tumors. Data are expressed as mean ± SD. 0.05 > *p > 0.01; **p% 0.01.266 Cancer Cell 14, 263–273, September 9, 2008 ª2008 Elsevier Ingemcitabine plus DC101, LLC tumors (nR 5 tumors per group)
were evaluated for volume, necrosis, and microvessel density 3
days after either paclitaxel or gemcitabine treatment with or with-
out prior administration of DC101. The results in Figures 4A–4C
and Figure S2B demonstrate significant reductions in tumor
volume and microvessel density and increases in overall tumor
necrosis in tumors treated with the combination of DC101 and
paclitaxel in comparison to treatment with paclitaxel alone. In
contrast, no significant differences were observed between
gemcitabine-treated and DC101 plus gemcitabine-treated tu-
mors. Also noteworthy is the observation that a single dose of
Figure 4. Assessment of LLC Tumor Volume, Microvessel Density,
Necrosis, and Long-Term Tumor Growth in Mice Treated with Pacli-
taxel or Gemcitabine in Combination with DC101
C57BL/6 mice bearing 500 mm3 LLC tumors (n = 4 or 5 mice per group) were
treated with paclitaxel (PTX) or gemcitabine (GEM) with or without DC101
administered 24 hr prior to the chemotherapy drug. Data are expressed as
mean ± SD. 0.05 > *p > 0.01; **p% 0.01; NS, not significant.
(A) Tumor volumes were assessed before and 3 days after treatment. The
change in tumor volume is shown.
(B and C) Three days after treatment, tumors were removed and evaluated for
microvessel density after CD31 staining for vessel structure. Data are pre-
sented as the number of vessel structures per field (n > 10 fields per tumor)
(B) or as necrosis (shown in green) on hematoxylin and eosin staining (C).
Scale bar = 100 mm. (See Figure S2B for summary of quantitative data.)
(D) In a separate experiment, LLC tumors implanted in C57BL/6 mice were al-
lowed to reach 500 mm3, at which point treatment with paclitaxel, gemcitabine
(administered at the maximum tolerated dose [MTD]), and/or DC101 was
initiated. Tumors were measured regularly using a caliper.c.
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the tumor vasculature, whereas a single injection of DC101 did
not cause a drop in microvessel density (Figure 4B).
Next, to explore the long-term antitumor effect of DC101 when
administered in combination with paclitaxel or gemcitabine, 53
105 LLC cells were implanted subcutaneously in the flanks of
C57BL/6 mice. When tumors reached 500 mm3, a single dose
of DC101 was administered, followed by paclitaxel or gemcita-
bine injection 24 hr later. The results in Figure 4D show that the
combination of DC101 and paclitaxel resulted in a substantial
antitumor effect manifested by a delayed tumor growth endpoint
in comparison to tumors treated with gemcitabine alone, pacli-
taxel alone, or the combination of DC101 and gemcitabine.
Comparable results for long-term enhanced treatment efficacy
were obtained for the combination of paclitaxel and DC101 in
C57BL/6 mice bearing B16F1 melanomas (Figure S3A). More-
over, we did not observe an enhanced treatment benefit when
DC101 was administered prior to doxorubicin (which does not in-
duce a CEP spike; see Figure 1) in C57BL/6 mice bearing LLC
(Figure S3B). Overall, these results reinforce our hypothesis
that the administration of an antiangiogenic drug immediately
prior to a chemotherapy drug that is competent to induce a rapid
CEP spike results in enhanced treatment efficacy, whereas little
or no enhanced antitumor activity is obtained when it is com-
bined with a chemotherapy drug that does not induce such
a CEP spike.
Superior Antitumor and Antiangiogenic Activities
in Id Mutant Mice Treated with Paclitaxel Compared
to Mice Treated with Gemcitabine
To further evaluate whether the treatment efficacy of paclitaxel
can be enhanced in the absence of a CEP spike, we tested the
antitumor effects of paclitaxel or gemcitabine in Id1+/Id3/
(Id) mutant mice and compared the treatment effects to those
observed in wild-type (WT) controls. Id mutant mice cannot mo-
bilize CEPs (Lyden et al., 1999) but are not deficient for other
bone marrow-derived proangiogenic cells such as TEMs, tu-
mor-associated macrophages, or tumor-associated neutrophils
(Ciarrocchi et al., 2007). Thus, enhanced efficacy of the chemo-
therapeutic drug can be ascribed directly to the lack of CEP
mobilization, as opposed to inhibition of other VEGF-responsive
bone marrow-derived cells. For this approach, LLC tumors im-
planted in mice were allowed to reach 500 mm3, at which point
treatment with either drug was initiated. Of note, a 3 day growth
delay in reaching the 500 mm3 point (20.3 days postimplantation
in Id mutant mice versus 17.2 days in WT mice) was observed in
tumors grown in Id mutant mice in comparison to the respective
tumors grown in WT mice, in line with previous observations
(Lyden et al., 1999; Shaked et al., 2006) (data not shown). Three
days after treatment, tumors (nR 5 tumors per group) were mea-
sured and then removed for evaluation of tumor hypoxia, vessel
perfusion, microvessel density, cell proliferation, and apoptosis.
Consistent with our hypothesis, Id loss in the host animal had no
influence on gemcitabine effectiveness, as no significant differ-
ences in tumor growth, perfusion, hypoxia, or microvessel den-
sity were observed. In contrast, a significant decrease in tumor
volume accompanied by an increase in tumor hypoxia and re-
duction in blood perfusion and microvessel density was ob-
served in tumors grown in Id mutant mice treated with paclitaxelCacompared to WT mice (Figures 5A–5C; Figure S4A–S4C). In ad-
dition, we found significant increases in tumor cell apoptosis in
paclitaxel-treated tumors grown in Idmutant mice in comparison
to treated tumors in WT mice. No significant differences in tumor
cell apoptosis or proliferation were observed in gemcitabine-
treated tumors grown in Id mutant versus WT mice (Figure 5D;
Figures S4D and S4E). Overall, these results provide further
evidence for the tumor growth-enhancing role that acutely mobi-
lized bone marrow-derived cells may play with respect to che-
motherapy drugs that induce their mobilization, followed by sub-
sequent homing to tumors. Blocking this chemotherapy-induced
host-reactive process resulted in increased treatment efficacy.
In previous studies using VDA treatment combined with
DC101, these marked short-term tumor-associated differences
were found to be predictive of long-term antitumor effects, in-
cluding prolonged survival (Shaked et al., 2006).
Rapid Induction in SDF-1a LevelsMay Account for Acute
CEP Mobilization after Treatment with Paclitaxel
To further assess the molecular mechanisms responsible for the
acute paclitaxel-induced CEP mobilization, plasma samples
from non-tumor-bearing C57BL/6 mice (n = 4 mice per group)
were obtained 4 hr after treatment with either paclitaxel or gem-
citabine administered at the MTD, and circulating VEGF-A, SDF-
1a, and G-CSF levels were evaluated, as these are all known to
mobilize bone marrow-derived cells including CEPs (Asahara
et al., 1999; Jin et al., 2006; Powell et al., 2005). As shown in
Figure 6A, both gemcitabine- and paclitaxel-treated mice ex-
hibited significant increases in circulating G-CSF plasma levels
and decreases in VEGF-A plasma levels, although not to the
same extent. However, levels of SDF-1a were significantly
induced only in the paclitaxel-treated mice in comparison to un-
treated control or gemcitabine-treated mice. No increases in
SDF-1a levels were observed in C57BL/6 mice (n = 4 mice per
group) 4 hr after they were treated with MTD doxorubicin, which
does not induce a CEP spike (Figure S5).
Jin et al. have recently reported that SDF-1a is stored in plate-
lets, and thus hemangiocytes as well as other bone marrow cells
expressing CXCR4 may rapidly mobilize from the bone marrow
and promote angiogenesis in response to acutely induced
SDF-1a secretion from circulating activated platelets (Jin et al.,
2006; Avecilla et al., 2004). To test this possibility, platelets iso-
lated from non-tumor-bearing C57BL/6 mice were incubated
in vitro for 4 hr with either 5 mM paclitaxel or 50 mM gemcitabine,
as previously described (Kroep et al., 1999). Subsequently,
platelet cell lysates were generated, and the concentration of
SDF-1a content was evaluated by ELISA. No significant differ-
ences were observed between any of the groups (data not
shown). Next, since Jin et al. (2006) reported that various cyto-
kines may induce release of SDF-1a from platelets, we asked
whether paclitaxel might indirectly promote the release of SDF-
1a from platelets. To this end, non-tumor-bearing C57BL/6
mice (n = 4 mice per group) were treated with either paclitaxel
or gemcitabine administered at the MTD. After 4 hr, mice were
bled by cardiac puncture, and platelets were isolated as de-
scribed in Experimental Procedures. Levels of SDF-1a were
evaluated in platelet lysates following normalization of protein
content. The results in Figure 6B show that a significant reduc-
tion in platelet SDF-1a content was observed only in micencer Cell 14, 263–273, September 9, 2008 ª2008 Elsevier Inc. 267
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Antiangiogenic Drugs and Chemotherapy EfficacyFigure 5. Assessment of LLC Volume, Hypoxia, Perfusion, Microvessel Density, Proliferation, and Apoptosis of Tumors in Id Mutant
or Wild-Type Mice after Paclitaxel or Gemcitabine Treatment
Id mutant (Idmut) and wild-type (WT) mice bearing 500 mm3 LLC tumors were treated with paclitaxel (PTX) or gemcitabine (GEM).
(A) Tumor volumes were assessed before and 3 days after treatment. The change in tumor volume is shown. Data are expressed as mean ± SD. 0.05 > *p > 0.01;
**p% 0.01. (See Figure S4 for summary of quantitative data.)
(B–D) Three days after treatment, tumors were removed and evaluated for vessel perfusion (blue) and hypoxia (green) (B), microvessel density (CD31 staining
in red) (C), and proliferation (red) and apoptosis (green) (D). Scale bars = 50 mm.treated with paclitaxel, as opposed to similar SDF-1a levels in
platelets obtained from untreated or gemcitabine-treated mice.
Taken together, these results suggest that paclitaxel may induce
the CEP spike at least in part by acute release of stored SDF-1a
from platelets.
Neutralizing SDF-1a Levels Enhances the Antitumor
Activity of Chemotherapy-Induced CEP Spikes
With the aim of assessing whether SDF-1a can account for the
rapid CEP mobilization observed after treatment with paclitaxel,
non-tumor-bearing C57BL/6 mice were treated with neutralizing
anti-SDF-1a antibodies (n = 5 mice per group). Twenty-four
hours later, mice were treated with either gemcitabine or pacli-
taxel, and 4 and 24 hr later, CEP levels were evaluated. The re-
sults in Figure 6C show that the SDF-1a neutralizing antibodies
substantially blocked induction of CEP levels within 24 hr in pac-
litaxel-treated mice. No significant differences were observed in
mice treated with gemcitabine. To further assess whether block-
ing SDF-1a might enhance paclitaxel treatment efficacy, mice
bearing LLC tumors were treated with polyclonal anti-SDF-1a
neutralizing antibodies 24 hr prior to either paclitaxel or gemcita-
bine treatment. Control mice were treated with nonspecific anti-
sera as described previously (Addison et al., 2000; Phillips et al.,
2003). The results in Figure 6D demonstrate that only in mice
treated with the combination of SDF-1a neutralizing antibodies
and paclitaxel was there evidence of enhanced antitumor effi-
cacy. This enhancement was not observed when the SDF-1a
neutralizing antibodies were combined with gemcitabine. Over-268 Cancer Cell 14, 263–273, September 9, 2008 ª2008 Elsevier Inall, these results suggest that the rapid increase in SDF-1a levels
accounts for the acute CEP mobilization after paclitaxel treat-
ment and that, as such, SDF-1a neutralizing antibodies can be
used as a de facto antiangiogenic/antivasculogenic-like treat-
ment strategy.
Increases in CEP and SDF-1a Plasma Levels in Patients
Treated with Paclitaxel
The preclinical results we obtained previously using VDAs, i.e.,
rapid elevations in CEP levels within 4 hr after drug administra-
tion, have been reproduced in a number of clinical studies
(Beerepoot et al., 2006; Farace et al., 2007; P. Nathan, personal
communication). Our next aim, therefore, was to evaluate
whether there is any indication that our aforementioned preclin-
ical results using chemotherapy can also be observed clinically.
To this end, a number of cellular and molecular assays were un-
dertaken using clinical samples from cancer patients treated
with chemotherapy at two different centers (the European Insti-
tute of Oncology [Milan] and University Medical Center Utrecht
[Utrecht, The Netherlands]). Cancer patients were treated with
paclitaxel or paclitaxel-based therapy, and the results were
compared to patients treated with gemcitabine or with doxorubi-
cin- or cisplatin-based therapies as indicated in detail in Exper-
imental Procedures. The results in Figure 7A show that, similar
to our preclinical observations, levels of CEPs significantly and
acutely increased from baseline in patients receiving pacli-
taxel-based therapy. Furthermore, significance was also
reached when paclitaxel-based therapy was compared to thec.
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Factors after Paclitaxel or Gemcitabine
Treatment and Impact of Anti-SDF-1a
Antibody on CEPs and Tumor Growth
(A) Non-tumor-bearing C57BL/6 mice (n = 4 mice
per group) were treated with paclitaxel (PTX) or
gemcitabine (GEM). Four hours later, mice were
bled by cardiac puncture and plasma was col-
lected. Levels of murine VEGF-A, SDF-1a, and
G-CSF were analyzed by ELISA.
(B) Analysis of SDF-1a content stored in isolated
circulating platelets from C57BL/6 mice 4 hr after
treatment with paclitaxel or gemcitabine at the
MTD.
(C) Non-tumor-bearing C57BL/6 mice (n = 5
mice per group) were treated with SDF-1a
neutralizing antibodies. Twenty-four hours later,
mice were treated with paclitaxel or gemcitabine.
After 4 and 24 hr, mice were bled from the retro-or-
bital sinus for evaluation of viable CEPs by flow
cytometry.
(D) LLC tumors were allowed to grow in C57BL/6
mice until the tumors reached 500 mm3, at which
point the mice were treated with polyclonal
SDF-1a neutralizing antibodies in combination
with either paclitaxel or gemcitabine. Control
mice received nonspecific antiserum treatment.
Tumors were measured regularly using a caliper.
Data are expressed as mean ± SD. 0.05 > *p >
0.01; **p% 0.01.other treatment groups. In addition, plasma concentrations of
SDF-1a, G-CSF, and VEGF were evaluated 4 hr after pacli-
taxel-based therapy and compared to the plasma concentra-
tions of patients treated with gemcitabine or with doxorubicin-
or cisplatinum-based therapies. The results in Figure 7B show
that SDF-1a plasma concentrations were rapidly and signifi-
cantly increased only in patients treated with paclitaxel-based
therapy, in contrast to patients treated with the other chemother-
apies. A nonsignificant trend was observed in both G-CSF and
VEGF plasma concentrations of both groups. Overall, based
on the preclinical data and preliminary clinical data obtained,
these results indicate that our preclinical mechanistic explana-
tion for the enhanced antitumor activity of bevacizumab when
administered in combination with certain chemotherapy drugs
may also hold clinically. Future prospective randomized clinical
trials will be necessary to confirm this.
DISCUSSION
Our results provide a new perspective regarding the impact that
conventional chemotherapy can have on tumor angiogenesis
and hence how combination with antiangiogenic drugs may
amplify the antitumor effects of chemotherapy. Previously, che-
motherapy has been reported to have the potential to cause local
tumor antiangiogenic effects by virtue of targeting cycling endo-
thelial cells in sprouting angiogenic blood vessel capillaries
within tumors (Browder et al., 2000; Klement et al., 2000; Miller
et al., 2001). But at approximately the same time, some chemo-Ctherapy drugs administered at MTD can cause a systemic host-
mediated counterregulatory response from the bone marrow,
comprised at least in part by acute mobilization of CEPs, which
subsequently has the potential to stimulate tumor angiogenesis
and vasculogenesis. This host response may not only help abro-
gate the potential local antiangiogenic effect but intrinsically
stimulate tumor vasculogenesis/angiogenesis as well, thus
acting to limit the duration of tumor responses induced by the
cytotoxic chemotherapy drug treatment.
Our results also provide a potential explanation of why not all
chemotherapy drugs will necessarily have their efficacy en-
hanced by the addition of an antiangiogenic agent when the
mechanism involves blunting CEP mobilization that is acutely in-
duced by the chemotherapy drug. It should be noted that our ex-
periments were conducted using only a single dose of DC101
prior to chemotherapy, for the purpose of inhibiting CEP mobili-
zation, as we demonstrated previously with VDAs (Shaked et al.,
2006). We have not tested the efficacy of repetitive combination
treatments, since it has already been demonstrated that DC101
has an antitumor effect due to antiangiogenic mechanisms when
administered in such a fashion as a single agent (Prewett et al.,
1999). The results may also be pertinent for explaining some of
the benefits of other therapeutic approaches that target CEPs.
For example, the administration of chemotherapy at close regu-
lar intervals using low, nontoxic doses with no prolonged breaks
(‘‘metronomic’’ chemotherapy) (Kerbel and Kamen, 2004) not
only avoids acute CEP mobilization but can even target CEPs
(Bertolini et al., 2003; Shaked et al., 2005b). It will also be ofancer Cell 14, 263–273, September 9, 2008 ª2008 Elsevier Inc. 269
Cancer Cell
Antiangiogenic Drugs and Chemotherapy EfficacyFigure 7. Levels of CEPs and G-CSF, SDF-
1a, and VEGF Plasma Concentrations in
Cancer Patients Four Hours after Treatment
with Various Chemotherapy Drugs Adminis-
tered at the MTD
Cancer patients (n = 30) were treated with pacli-
taxel (n = 8) or paclitaxel plus carboplatin (n = 4)
(both of which were designated as PTX-based
therapy); gemcitabine (GEM) (n = 8); epirubicin,
cisplatin, and capecitebin (n = 5) (ECX); or doxoru-
bicin with or without cyclophosphamide (n = 5)
(Dox-based therapy). Four hours later, patients
were bled intravenously for evaluation of CEPs
(n = 12 for PTX-based; n = 18 for GEM/ECX/Dox-
based) (A) as well as G-CSF (n = 3 for PTX-based;
n = 10 for ECX/Dox-based), SDF-1a (n = 12 for
PTX-based; n = 15 for GEM/ECX/Dox-based),
and VEGF (n = 3 for PTX-based; n = 10 for ECX/
Dox-based) plasma concentrations (B). Results
were normalized to the baseline level of each pa-
tient to reduce variability due to tumor type, stage,
and values obtained from two different centers.
Data are expressed as mean ± SEM. 0.05 > *p >
0.01; **p% 0.01.interest to determine whether and to what degree other types of
bone-marrow derived proangiogenic cells (Grunewald et al.,
2006; De Palma et al., 2005; Udagawa et al., 2006) may be
induced (or suppressed) by MTD chemotherapy and thus poten-
tially contribute to tumor recovery after treatment (or response).
Notably, some of these populations, e.g., Gr1+/CD11b+ myeloid
cells, may not be suppressed by drugs that target the VEGF-A
pathway of angiogenesis (Shojaei et al., 2007). However, our ex-
periments performed in Id mutant mice indicate that CEPs play
the major role in the systemic response, as these animals are
not deficient for other proangiogenic cells (Ciarrocchi et al.,
2007).
Our results raise a number of important questions relevant to
antiangiogenic drugs and the role of CEPs in tumor angiogene-
sis. For example, as antiangiogenic small-molecule oral receptor
tyrosine kinase inhibitors (RTKIs), which target multiple RTKs
including VEGF receptors, have not yet shown an ability to
enhance the efficacy of conventional chemotherapy in phase III
trials, in contrast to bevacizumab (Kerbel, 2008), could this be
due to an inability of such drugs to block CEP mobilization? In
this regard, we have recently reported that one such drug, suni-
tinib, can cause marked elevations in multiple circulating growth
factors, cytokines, and chemokines in a dose-dependent and tu-
mor-independent fashion (Ebos et al., 2007). These factors in-
clude VEGF, PlGF, G-CSF, SDF-1a, and SCF. Since the recep-
tors for G-CSF and SDF-1a are not affected by sunitinib, and
since both G-CSF and SDF-1a are known to mobilize CEPs (Asa-
hara et al., 1999; Jin et al., 2006; Powell et al., 2005), targeting
VEGF receptors and c-kit using a drug such as sunitinib may
not be sufficient to blunt chemotherapy-induced CEP spikes
when they occur. Second, might our results help resolve some
of the ongoing controversy regarding the importance of CEPs
in tumor angiogenesis? Most studies have shown low (Peters
et al., 2005) or even nonexistent (Purhonen et al., 2008) incorpo-
ration of CEPs in tumor blood vessels in mouse tumor models
(Bertolini et al., 2006); however, as we previously reported for
VDAs—which are not yet clinically approved and are being270 Cancer Cell 14, 263–273, September 9, 2008 ª2008 Elsevier Inctested only in small numbers of patients—some commonly
used chemotherapy drugs such as paclitaxel can also cause a ro-
bust mobilization of CEPs that subsequently can home to the
drug-treated tumors and incorporate into newly forming vessels.
Importantly, such incorporation may be influenced by damage to
the tumor (neo)vasculature, thus creating the physiologic need
(‘‘signal’’) for rapid replacement of damaged or destroyed endo-
thelium in the tumor vasculature. Rapid mobilization of CEPs and
homing to vessels damaged by adverse cardiovascular events
(Urbich and Dimmeler, 2004) could be taken as a model for
this host process in the context of cytotoxic drug-induced dam-
age to the tumor vasculature. In this regard, while VDAs are
known to cause damage to the tumor vasculature, such a prop-
erty is less appreciated with respect to chemotherapy. However,
there is an expanding literature of chemotherapy-induced dam-
age to endothelial cells in the tumor vasculature (Browder et al.,
2000; Klement et al., 2000; Miller et al., 2001), which in some
cases can be very rapid (Farace et al., 2007). Indeed our own re-
sults, presented here, indicate that MTD chemotherapy can
cause rapid drops in tumor microvessel density, even after a sin-
gle MTD dose as shown in Figure 4B.
Our preclinical results are supported by limited clinical obser-
vations testing levels of CEPs and SDF-1a, G-CSF, and VEGF
plasma concentrations in cancer patients treated with chemo-
therapy using paclitaxel. Jin et al. (2006) have recently suggested
that elevated levels of SDF-1a induce mobilization of CXCR4+
cells from the bone marrow, perhaps including CEPs, as the ma-
jority of them express CXCR4 (Yamaguchi et al., 2003; Athanas-
sakis et al., 2001). Based on our preliminary results, platelets
could be one source of the released SDF-1a. The rapid induction
of various cytokines may promote platelet activation and hence
cause the release of SDF-1a stored in platelets (Jin et al., 2006;
Rafii et al., 2008). It has also been suggested that mobilization of
activated megakaryocytes from the bone marrow niche can up-
regulate levels of SDF-1a (Avecilla et al., 2004). Finally, it will be
of interest to evaluate the contribution of the mechanism we have
proposed here to account for antiangiogenic drug-mediated.
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Antiangiogenic Drugs and Chemotherapy Efficacyenhancement of standard chemotherapy, using drugs such as
bevacizumab, relative to other proposed mechanisms. These
include transiently induced vessel normalization (Jain, 2005;
Winkler et al., 2004) or enhancement of the extent of local dam-
age to the tumor vasculature mediated by chemotherapy, in the
clinical setting.
EXPERIMENTAL PROCEDURES
Blood Samples Obtained from Cancer Patients
Blood samples were collected from cancer patients receiving chemotherapy.
Sixteen patients with stage IV metastatic breast cancer were treated with ei-
ther paclitaxel (n = 8) or gemcitabine (n = 8) at the European Institute of Oncol-
ogy (Milan). The study followed the rules of the European Institute of Oncology
ethics committee, and written informed consent was obtained from all pa-
tients. In addition, four patients with ovarian cancer were treated with carbo-
platin and paclitaxel (paclitaxel-based therapy); five patients were treated
with either doxorubicin monotherapy or doxorubicin in combination with cy-
clophosphamide (doxorubicin-based therapy) for malignant sarcoma and
breast cancer, respectively; and five patients with esophageal cancer were
treated with the combination of epirubicin, cisplatin, and capecitebine
(cisplatin-based therapy) at the clinic of the Department of Medical Oncology,
University Medical Center Utrecht (Utrecht, The Netherlands). The study was
approved by the institutional ethical review board of University Medical Center
Utrecht, and written informed consent was obtained from all patients.
Tumors and Animal Models
Eight- to twelve-week-old C57BL/6 or BALB/c mice (obtained from The Jack-
son Laboratory–West, Sacramento, CA, USA) were treated with chemother-
apy drugs. Lewis lung carcinoma (LLC) cells (5 3 105; American Type Culture
Collection) were subcutaneously implanted into immunocompetent C57BL/6
mice (The Jackson Laboratory) or C57BL/6 mice previously irradiated and
then transplanted with GFP+ bone marrow cells or were injected into
Id1+/Id3/ (Idmut) mice and WT C57BL/6 mice. B16F1 melanoma cells (5 3
105; American Type Culture Collection) were implanted into the flanks of immu-
nocompetent C57BL/6 mice. Tumor size was assessed regularly with Vernier
calipers using the formula width2 3 length 3 0.5. When tumors reached
500 mm3, treatment was initiated. All mice used for in vivo studies were ran-
domly grouped (n = 4–6 per group). All animal studies were performed accord-
ing to the Sunnybrook Health Sciences Centre Animal Care Committee (Toronto)
and the Canadian Council on Animal Care or the Institutional Animal Care and
Use Committee of Memorial Sloan-Kettering Cancer Center (New York).
Drugs and MTD Drug Concentrations
The following antibodies were used for in vivo therapy: 800 mg/mouse DC101
(ImClone Systems Inc.), a rat monoclonal blocking antibody specific for mouse
VEGFR2/Flk-1; 50 mg/mouse monoclonal SDF-1a neutralizing antibodies (R&D
Systems); 50 mg/mouse goat polyclonal anti-SDF-1a neutralizing antibodies or
goat nonspecific antisera control after Fc fragment digestion; and 5 mg/kg G6-
31, a monoclonal anti-mouse/human VEGF neutralizing antibody (Genentech).
All doses had been previously determined for optimal activity (Prewett et al.,
1999; Schober et al., 2003; Phillips et al., 2003; Liang et al., 2006). Chemother-
apy drugs were administered near or at the MTD as indicated in Table S1. All
drugs were administered intraperitoneally as a bolus injection. Control mice
received the relevant vehicles. DC101, G6-31, and SDF-1a neutralizing anti-
bodies when used with chemotherapy were administered 24 hr prior to the
chemotherapy drug injection.
Flow Cytometry
For preclinical evaluation of viable CEPs, blood was obtained from anesthe-
tized mice via retro-orbital sinus bleeding and prepared for CEP labeling as de-
scribed previously (Bertolini et al., 2003; Shaked et al., 2005a). For clinical
samples, CEPs were evaluated in patients as described previously (Bertolini
et al., 2006). For detailed information, see Supplemental Experimental
Procedures.
For evaluation of GFP+ bone marrow-derived cells, hemangiocytes, and
TEMs resident in tumors, 100–300 mm3 of tumor tissue (n = 5 samples perCagroup) was prepared as a single-cell suspension as described previously
(Baeten et al., 2002). GFP+ cells expressing CD45, CXCR4, and VEGFR1
were defined as hemangiocytes (Jin et al., 2006). GFP+ cells expressing
CD45, Tie2, and CD11b were defined as TEMs (De Palma et al., 2005). At least
50,000 cells per sample were acquired. All bone marrow cell types were
plotted as the absolute cell number in 10,000 cells.
For all flow cytometry experiments, CD133 was purchased from Miltenyi
Biotec, Tie2 was produced in-house (Sunnybrook Health Sciences Centre),
and VEGFR1 was purchased from R&D Systems. All other antibodies were
purchased from BD Biosciences.
Quantitation and Visualization of Tissue Necrosis, Hypoxia, Vessel
Perfusion, Tumor Cell Proliferation, and Apoptosis
Tissue processing and immunohistochemistry were performed as described
previously (Shaked et al., 2006). For detailed information, see Supplemental
Experimental Procedures.
Microscopic Image Acquisition and Analysis
Tumor sections were visualized under a Zeiss Axioplan 2 microscope. Images
were captured with a Zeiss AxioCam digital camera connected to the micro-
scope using AxioVision 3.0 software. The number of fields per tumor sample
varied from four to ten depending on the tumor size. Analysis of tumor hypoxia,
vessel perfusion, and necrosis as well as tumor cell proliferation and apoptosis
was carried out by calculating the fraction of the tumor area staining positive
for the indicated parameter, using Adobe Photoshop 6.0 software (Adobe Sys-
tems). For analysis of microvessel density, the total number of vascular struc-
tures (CD31+) per field was counted per tumor sample. At least ten fields per
tumor representing all tumor areas were taken (nR 5 tumors per group).
Analysis of VEGF-A, SDF-1a, and G-CSF Plasma Concentrations
Blood samples obtained by cardiac puncture from mice under anesthesia or
intravenously from cancer patients were collected in either Microtainer (Becton
Dickinson) plasma separating tubes (for mice) or EDTA tubes (for humans),
centrifuged at 4C, and subsequently stored at 70C until assayed. Levels
of mouse or human VEGF-A, SDF-1a, and G-CSF were assessed using com-
mercially available sandwich ELISAs (R&D Systems).
Isolation of Platelets and Analysis of SDF-1a
Experiments were performed as described previously (Jin et al., 2006). For
detailed information, see Supplemental Experimental Procedures.
Bone Marrow Transplantation
Experimental procedures were carried out as described previously (Shaked
et al., 2006). For detailed information, see Supplemental Experimental
Procedures.
Statistical Analysis
Data are expressed as mean ± SD, and the statistical significance of differ-
ences in mean values was assessed by Student’s two-tailed t test. Differences
between designated groups compared to control untreated group (unless in-
dicated otherwise) were considered significant at values of 0.05 > p > 0.01
(*) or p% 0.01 (**). For human samples, data are expressed as mean ± SEM.
Comparisons between baseline and 4 hr posttreatment were made by paired
t test. Comparisons between groups of patients treated with paclitaxel-based
versus other chemotherapy-based therapies were made by unpaired t test.
Significance was set as 0.05 > p > 0.01 (*) or p% 0.01 (**).
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, one table, and six figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/14/3/
263/DC1/.
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